EGFR Resisters

@EGFRResisters

A group of EGFR+ lung cancer patients who are resistant to targeted treatment. Sharing support & research news, accelerating research, improving outcomes.

Worldwide!
Vrijeme pridruživanja: kolovoz 2017.

Tweetovi

Blokirali ste korisnika/cu @EGFRResisters

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EGFRResisters

  1. Prikvačeni tweet
    prije 5 sati

    Read the EGFR Resisters February Newsletter: Self-funded research project moving ahead with LUNGevity and our first EGFR Resisters Patient Summit to take place in Sept! Lots of research info too.

    Poništi
  2. 31. sij
    Poništi
  3. proslijedio/la je Tweet
    21. sij

    Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination w/osimertinib for the treatment of patients with EFGR mutations that progressed after treatment with osimertinib alone.

    Poništi
  4. 20. sij

    Thanks to research, has been LIVING with lung cancer for 11 years. !

    Poništi
  5. 17. sij

    DUKE EGFR STUDY! Do you (or your loved one) have positive ? Your voice can help researchers inform drug development, policy, and education. Read more here.

    Poništi
  6. 17. sij

    Because of EGFR research, Jolie Lerner is looking forward to celebrating a major milestone birthday with her childhood bff in 2020!

    Poništi
  7. 16. sij

    Because of EGFR research, Sarah Christ looks forward to seeing her daughter graduate from high school and sending her off to college in 2020.

    Poništi
  8. proslijedio/la je Tweet
    14. sij

    So happy to see the important work being done by on transformation as a resistance mechanism to TKIs.

    Poništi
  9. proslijedio/la je Tweet
    14. sij

    Are we moving towards upfront combination approaches for EGFR-positive lung cancer? But then what...? Excellent discussion by LUNGevity awardee Dr.

    Poništi
  10. proslijedio/la je Tweet
    14. sij

    Important trial for patients who have progressed on first-line osimertinib -

    Poništi
  11. proslijedio/la je Tweet
    14. sij

    Fabulous overview of Osi resistance by Re-biopsy critical to understand it & proceed. Both liquid & tissue biopsy ideal, but not always realistic. She discusses pros & cons, but only tissue can find histological change.

    Poništi
  12. proslijedio/la je Tweet
    14. sij

    Great point by and - we always publish positive experiences, but we must publish negative as well because clinicians need that info to make the best AND SAFEST treatment decisions!

    Poništi
  13. proslijedio/la je Tweet
    14. sij

    Jacqulyne Robichaux summarizing the state of the field for EGFR and HER2 Exon 20 mutant lung cancer ⁩ ⁦

    Poništi
  14. proslijedio/la je Tweet
    14. sij

    Why do Exon 20 mutations not respond to EGFR TKIS? Because the mutation reduces the size of the drug-binding pocket. Excellent talk by Dr Jacqulyn Robichaux

    Poništi
  15. proslijedio/la je Tweet
    14. sij

    To gain a deeper understanding of the effect of Exon 20 mutations on the drug-binding pocket, sensitivity to TKIs and the genomic landscape of exon 20 mutations, Jacqulyne Robichaux from presents her study at .

    Poništi
  16. proslijedio/la je Tweet
    14. sij

    A great number of animal model studies described by this morning at are not yet ready to be shared online - but stay tuned. Very interesting data that will be published soon re tumor suppression genes in EGFR-mutant .

    Poništi
  17. proslijedio/la je Tweet
    14. sij

    Excellent discussion by Dr on the use of mouse models to understand mechanisms of resistance to EGFR TKIs

    Poništi
  18. proslijedio/la je Tweet
    14. sij

    Cancer is too personal for , and research advances have kept her and others alive who have disease. Finding your people online who mutually educate/commiserate is so important.

    Poništi
  19. proslijedio/la je Tweet
    14. sij
    Poništi
  20. proslijedio/la je Tweet
    14. sij

    ⁩ ⁦⁩ talking about the power of community and advocacy and how it can be life-changing and life-saving ⁩ ⁦

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·